The Beat Childhood Cancer Research Consortium is a group of 50+ universities and children’s hospitals that offer a worldwide network of childhood cancer clinical trials coordinated by Atrium Health Levine Children’s in Charlotte, North Carolina. These trials are based on the research from a group of closely collaborating investigators who are linked with laboratory programs developing novel therapies for high-risk pediatric cancers.
Our mission is to continue to use precision medicine to bring forward new therapies for children with cancer with the goal of finding a cure for these patients.
FIRSTS:
- Treated the FIRST patient on BCC018 protocol adding Naxitamab to Induction Therapy for High-Risk Neuroblastoma (Kapi’olani Medical Center)
- Treated the FIRST brain tumor (DIPG) patient with patient-specific activated T-Cells against their cancer (xALT infusion) on the BCC017 protocol (University of Florida).
- Established a national Precision Medicine Program to include Molecular Tumor Boards and a personalized approach to patient care.
Several publications were released in 2022, notably TB-403 Paper, Landscape Paper, and Nifurtimox Paper (in submission). In addition, nine posters and oral presentations were also presented at AACR, ASCO, SIOP and ASPHO conferences in 2022.
Learn more about:
Pediatric Oncology Translational Research Laboratory
To support the Beat Childhood Cancer Research Consortium, visit our secure giving platform:
For more information, contact:
Abigail Moore, BA, CCRP
Program Manager, Beat Childhood Cancer Research Consortium
Pediatric Oncology, Levine Children’s Hospital